glp-1 injection vs pill Shots: What to Consider Oral GLP-1 Weight Loss: Pills

Closed Captioning Feedback HealthLine is a local public television program presented by PBS Fort Wayne Parkview Health GLP-1 Medications in Weight Loss and Diabetes Season 2024 Episode 3823 | 28m 1sVideo has Closed Captions This week on HealthLine, host Mark Evans is joined by Ryan Singerman, D.O

doi: 10.1371/journal.pone.0161886 105

*Correspondence: Miriam Kolko, [email protected] This article was submitted to Neurodegeneration, a section of the journal Frontiers in Neuroscience Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers

Rotating injection sites with each doserather than using the same location repeatedlyallows tissue recovery and reduces cumulative irritation

Findings: RCTSURMOUNT-2 trial - Tirzepatide vs Placebo for Weight Loss in Diabetes, Lancet (2023) [PubMed abstract] Design: Randomized, placebo-controlled trial (N=938 | length = 72 weeks) in overweight diabetics (mean BMI 36 | mean A1C 8.02%) Treatment: Tirzepatide 10 mg once weekly vs Tirzepatide 15 mg once weekly vs Placebo Primary outcome: Coprimary endpoints were the percent change in body weight from baseline and body weight reduction of 5% or higher Results: Primary outcome (% reduction in weight): Tirzepatide 10 mg - 12.8%, Tirzepatide 15 mg - 14.7%, Placebo - 3.2% (p 35 - 68.9% Randomized treatment groups Group 1 (374 patients): Tirzepatide titrated to the maximum tolerated dose of 10 mg or 15 mg once weekly Group 2 (376 patients): Semaglutide titrated to the maximum tolerated dose of 1.7 mg or 2.4 mg once weekly Tirzepatide was initiated at a dose of 2.5 mg once weekly, and the dose was increased by 2.5 mg every 4 weeks until a maximum tolerated dose of 10 mg or 15 mg was reached

[DOI] [PubMed] [Google Scholar] 47.Hansen JS, de Mar S, Jones HA, Gransson O, Lindkvist-Petersson K